Maptelligent Inc. (MAPT)
Market Closed
16 Oct, 08:00 PM
OTC PINK OTC PINK Primary $
0. 00
0
0%
$
158.53K Market Cap
0 P/E Ratio
- Div Yield
10,000 Volume
0 Eps
$ 0
Previous Close Want to track MAPT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform
Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its CNS pipeline, initiating two new ARO-MAPT phase 2 trials and advancing four additional CNS candidates into the clinic by end of 2027. Recent milestones include strong Redemplo phase 3 data, positive ARO-DIMER-PA results, and FDA STAR program entry for Redemplo, supporting a robust long-term growth outlook.
Seekingalpha | 4 days ago
2026 © Marketlog. All Rights Reserved.
